Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy

被引：2
|
作者：
Fujimura, Taku [1 ]
Tanita, Kayo [1 ]
Sato, Yota [1 ]
Kambayashi, Yumi [1 ]
Furudate, Sadanori [1 ]
Tsukada, Akira [1 ]
Hashimoto, Akira [1 ]
Aiba, Setsuya [1 ]
机构：
[1] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi, Japan
来源：
CASE REPORTS IN ONCOLOGY | 2018年 / 11卷 / 01期
关键词：
Erythrodermic mycosis fungoides; Mogamulizumab; Etoposide;
D O I：
10.1159/000486278
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sezary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy. (C) 2018 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码：29 / 32
页数：4
相关论文
共 50 条
  • [41] Erythrodermic Mycosis Fungoides Presenting with Ichthyosiform Eruptions Under Extracorporal Photopheresis
    Mueller, C. S. L.
    Zdebik, A.
    Pfoehler, C.
    Vogt, T.
    AKTUELLE DERMATOLOGIE, 2016, 42 (10) : 424 - 427
  • [42] TREATMENT OF MYCOSIS FUNGOIDES
    TRONNIER, H
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1971, 96 (40) : 1569 - &
  • [43] Erythrodermic mycosis fungoides with large cell transformation: An unusual and complicated case
    Lombardi, Conner, V
    Glosser, Logan D.
    Hopper, Wade
    Veria, Spiro
    Awad, Mohammed T.
    Garg, Anu
    SAGE OPEN MEDICAL CASE REPORTS, 2022, 10
  • [44] Mogamulizumab-Associated Rash in Patients With Mycosis Fungoides and Sezary Syndrome
    Foley, Nicole
    Minor, Chelsea
    Musiek, Amy
    Mehta-Shah, Neha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S464 - S464
  • [45] (P068) A history of mycosis fungoides: from Alibert to mogamulizumab
    Johnson, Nicholas A.
    Venables, Zoe C.
    Mistry, Khaylen
    Levell, Nick J.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I166 - I166
  • [46] Differences in the miRNA expression profiles of erythrodermic mycosis fungoides and Sezary syndrome
    Rittig, Anne Hald
    Lindahl, Lise Maria
    Johansen, Claus
    Odum, Niels
    Iversen, Lars
    Litman, Thomas
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : S3 - S4
  • [47] ERYTHRODERMIC MYCOSIS-FUNGOIDES WITH EARLY LYMPH-NODES INVOLVEMENT
    DORRONSORO, MLG
    MARTINEZPENUELA, JM
    QUIROGA, J
    CABARCOS, A
    REVISTA CLINICA ESPANOLA, 1984, 172 (05): : 297 - 299
  • [48] Familial cutaneous mycosis fungoides: Successful treatment with a combination of gemcitabine and alemtuzumab
    Weder, P
    Anliker, M
    Itin, P
    Bargetzi, M
    DERMATOLOGY, 2004, 208 (03) : 281 - 283
  • [49] Successful treatment of hypopigmented mycosis fungoides in a pediatric patient with excimer laser
    Taylor, Laura
    Perna, Danielle
    Callen, Jeffery
    Owen, Cindy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB206 - AB206
  • [50] FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sezary Syndrome
    Kasamon, Yvette L.
    Chen, Haiyan
    de Claro, R. Angelo
    Nie, Lei
    Ye, Jingjing
    Blumenthal, Gideon M.
    Farrell, Ann T.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7275 - 7280
12345